Chemokines as therapeutic targets in renal cell carcinoma

Targeting novel pathways associated with tumor angiogenesis, invasion and immunity, may lead to improvement in patient outcomes for renal cell carcinoma. Chemokines potentiate tumor growth, metastasis, angiogenesis and immune evasion through interactions with stromal cells and neoplastic cells. Further understanding of the mechanisms involved in chemokine-mediated angiogenesis and metastasis may lead to improved therapeutic strategies in this disease. Interactions between chemokine expression and signaling, and the VEGF and hypoxia-inducible factor pathways offer important opportunities to intervene in the process of renal cell carcinoma proliferation, angiogenesis and invasion. Modulation of the CXCR3/CXCR3-ligand or the CXCR4/CXCL12 biologic axis may be potential therapeutic targets for the treatment of renal cell carcinoma. Furthermore, combination treatment with agents targeting chemokine signaling with therapies directed at angiogenesis and tumor immunity may lead to improved outcomes in this disease.

[1]  P. A. van den Brandt,et al.  Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis , 2008, Clinical Cancer Research.

[2]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[3]  David B Seligson,et al.  Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[4]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[5]  R. Figlin,et al.  Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy , 2007, Journal of immunotherapy.

[6]  J. Leppert,et al.  The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. , 2007, The Journal of urology.

[7]  Mark A Rosen,et al.  Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference , 2007, Clinical Cancer Research.

[8]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[9]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[10]  Judong Pan,et al.  Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis , 2006, Molecular Cancer.

[11]  H. Friess,et al.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. , 2006, Cancer letters.

[12]  F. Ito,et al.  Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1‐type immune response , 2006, Cancer science.

[13]  S. Hwang,et al.  Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.

[14]  F. Wamunyokoli,et al.  A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. , 2006, Cancer research.

[15]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[16]  H. Sakurai,et al.  Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. , 2006, Cancer research.

[17]  C. Taylor,et al.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.

[18]  M. Burdick,et al.  CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.

[19]  H. Spring,et al.  Chemokines direct endothelial progenitors into tumor neovessels. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Abdel‐Mageed,et al.  Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. , 2005, Cancer research.

[21]  R. Figlin,et al.  The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma1 , 2005, The Journal of Immunology.

[22]  G. Hortobagyi,et al.  CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1 Breast Cancer , 2005, Clinical Cancer Research.

[23]  G. Semenza,et al.  Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .

[24]  Qingliang Wang,et al.  The Expression of Functional Chemokine Receptor CXCR4 Is Associated with the Metastatic Potential of Human Nasopharyngeal Carcinoma , 2005, Clinical Cancer Research.

[25]  A. Sica,et al.  Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1α* , 2005, Journal of Biological Chemistry.

[26]  R. Greil,et al.  Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma , 2005, Clinical Cancer Research.

[27]  M. Burdick,et al.  Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. , 2005, Cancer research.

[28]  P. Galle,et al.  Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer , 2005, Clinical Cancer Research.

[29]  H. Ishikura,et al.  Up‐regulation of the interferon γ (IFN‐γ)‐inducible chemokines IFN‐inducible T‐cell α chemoattractant and monokine induced by IFN‐γ and of their receptor CXC receptor 3 in human renal cell carcinoma , 2005 .

[30]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[31]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[32]  F. Balkwill.  The significance of cancer cell expression of the chemokine receptor CXCR4. , 2004, Seminars in cancer biology.

[33]  A. Mantovani,et al.  Chemokines in neoplastic progression. , 2004, Seminars in cancer biology.

[34]  A. Ravaud,et al.  Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial , 2003, British Journal of Cancer.

[35]  S. Saccani,et al.  Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.

[36]  R. Figlin,et al.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[38]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Burdick,et al.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.

[40]  M. Ratajczak,et al.  CXCR4–SDF-1 Signalling, Locomotion, Chemotaxis and Adhesion , 2003, Journal of Molecular Histology.

[41]  F. Balkwill.  Chemokine biology in cancer. , 2003, Seminars in immunology.

[42]  B. Clotet,et al.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication , 2002, AIDS.

[43]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[44]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[45]  J. Broach,et al.  A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists* , 2002, The Journal of Biological Chemistry.

[46]  M. Probst-Kepper,et al.  CXCR4/CXCL12 expression and signalling in kidney cancer , 2002, British Journal of Cancer.

[47]  A. Mantovani,et al.  Analysis of the Gene Expression Profile Activated by the CC Chemokine Ligand 5/RANTES and by Lipopolysaccharide in Human Monocytes1 , 2002, The Journal of Immunology.

[48]  P. Murphy,et al.  Chemokines and the molecular basis of cancer metastasis. , 2001, The New England journal of medicine.

[49]  R. Strieter.  Chemokines: Not just leukocyte chemoattractants in the promotion of cancer , 2001, Nature Immunology.

[50]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[51]  M. Burdick,et al.  The Role of the CC Chemokine, RANTES, in Acute Lung Allograft Rejection1 , 2000, The Journal of Immunology.

[52]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[53]  T. Olencki,et al.  Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .

[54]  J. Finke,et al.  The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.

[55]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[56]  M. Parmentier,et al.  Genomic organization and promoter characterization of human CXCR4 gene 1 , 1998, FEBS letters.

[57]  E. Ohlstein,et al.  Chemokine Receptors in Human Endothelial Cells , 1998, The Journal of Biological Chemistry.

[58]  Armen B. Shanafelt,et al.  The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.

[59]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[62]  R. Halaban.  Molecular correlates in the progression of normal melanocytes to melanomas. , 1993, Seminars in cancer biology.

[63]  Z. Brown,et al.  Chemokine Receptors , 2006, Treatments in respiratory medicine.

[64]  G. Nuovo,et al.  Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. , 2006, Cancer research.

[65]  M. Atkins,et al.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M. Burdick,et al.  Chapter 2.6 – CXC Chemokines in Angiogenesis , 2002 .

[67]  T. Olencki,et al.  Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[69]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.